狼疮肾炎早期蛋白尿达标不保证12个月完全缓解
该队列研究纳入132例活检证实的狼疮肾炎患者,评估EULAR推荐的3个月和6个月蛋白尿早期达标对12个月完全肾脏缓解(CRR)的预测价值。结果显示早期达标与12个月CRR独立相关,但两项指标敏感性高、特异性中等;基线肾病范围蛋白尿患者中早期达标的预测价值有限。
要点
- EULAR 3个月和6个月蛋白尿达标与12个月CRR独立相关(OR分别为7.38和10.6)。
- 两项早期达标指标敏感性86-89%、特异性40-45%,未达标提示后续CRR概率降低。
- 基线肾病范围蛋白尿患者中,早期达标对12个月CRR的预测特异性更低。
核心结论
- 未达到EULAR 3个月和6个月蛋白尿目标提示12个月应答不佳的风险升高。
- 基线肾病范围蛋白尿患者中,早期达标对12个月CRR的预测价值有限。
研究设计与样本
- 活检证实的狼疮肾炎患者队列研究,共纳入132例患者。
- 采用回归模型分析与12个月CRR独立相关的因素,并计算EULAR 3个月和6个月蛋白尿目标的预测性能指标。
主要发现
- 132例患者中92例(69.7%)在12个月达到CRR。
- EULAR 3个月达标与12个月CRR独立相关(OR 7.38,95%CI 2.84-20.4)。
- EULAR 6个月达标与12个月CRR独立相关(OR 10.6,95%CI 3.74-32.4)。
- 基线蛋白尿每增加1 g与CRR呈负相关(两个模型中OR分别为0.77和0.75)。
- 两项早期达标指标敏感性86-89%、特异性40-45%,阴性似然比0.27-0.31。
关键数值与推荐
- EULAR推荐狼疮肾炎早期蛋白尿降低目标:3个月≥25%、6个月≥50%。
- 肾病范围蛋白尿患者中,3个月和6个月目标的特异性分别为0.30和0.17。
临床怎么用
- 可将EULAR 3个月和6个月蛋白尿未达标作为12个月应答不佳的预警信号。
- 对基线肾病范围蛋白尿患者,不应仅凭早期蛋白尿达标预判12个月CRR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: EULAR recommends early proteinuria-reduction targets in LN (≥25% at 3 months and ≥50% at 6 months). We examined the predictive value of these targets for achieving complete renal response (CRR) at 12 months, a surrogate for favourable long-term outcomes. METHODS: We examined data from a cohort study of patients with biopsy-proven LN. Regression models were applied to identify independent associations with 12-month CRR. Performance metrics for EULAR 3- and 6-month targets were calculated for the whole cohort, and for patients with nephrotic or subnephrotic baseline proteinuria. RESULTS: A total of 132 patients with biopsy-proven LN were included; 92 (69.7%) achieved CRR at 12 months. Attainment of EULAR-proposed 3- and 6-month targets was independently associated with 12-month CRR [odds ratio (OR) 7.38, 95% CI 2.84-20.4 at 3 months; OR 10.6, 95% CI 3.74-32.4 at 6 months]. Higher baseline proteinuria levels were inversely associated with CRR in both models (OR 0.77 and 0.75 per 1 g increase, respectively). Both targets had high sensitivity (86-89%) but moderate specificity (40-45%), while negative likelihood ratios (0.27-0.31) suggested that failure to achieve these early targets meaningfully reduced the probability of subsequent 12-month CRR. In patients with nephrotic-range proteinuria, both targets showed lower specificity (0.30 and 0.17), suggesting limited ability to predict 12-month CRR. CONCLUSION: Failure to achieve the EULAR 3- and 6-month proteinuria targets serves as a warning sign for suboptimal response at 12 months. In patients with baseline nephrotic-range proteinuria attainment of early response has limited predictive value for 12-month CRR.
引用
- Pappa M, Drougkas K, Pieta A, et al. Attainment of early targets does not ensure a complete response at 12 months in lupus nephritis, especially in nephrotic-range proteinuria. Rheumatology (Oxford). 2026. PMID: 42584078. doi:10.1093/rheumatology/keag411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。